Minovar (603538.SH): The new active ingredient in Xuancheng Minovatai has passed the FDA on-site inspection for the first time

Zhitongcaijing · 2d ago

Zhitong Finance App News, Minova (603538.SH) announced that the company's holding subsidiary Xuancheng Minova Pharmaceutical Co., Ltd. (hereinafter referred to as “Xuancheng Minova”) underwent a cGMP (Current Pharmaceutical Production Quality Management Specification) on-site inspection by the US Food and Drug Administration (“FDA”) from June 22 to June 26, 2026. The scope of inspection covered quality systems, material management systems, production management systems, equipment and facility systems, packaging and labeling systems, laboratory control systems, etc. Product tested this time: tildipirosin (tildipirosin).

On November 4, 2026, Xuancheng Minova received an on-site inspection report (EIR, Preventive Inspection Report) issued by the FDA. The report showed that Xuancheng Minova (No. 9 Meizigang Road, Xuancheng High-tech Industrial Development Zone, Anhui) has passed this cGMP on-site inspection.